Page last updated: 2024-11-07

bn 50739

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BN 50739: platelet activating factor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115002
MeSH IDM0177656

Synonyms (13)

Synonym
gtpl1851
9-(2-chlorophenyl)-14-{2-[(3,4-dimethoxyphenyl)sulfanyl]ethanethioyl}-3-methyl-17-thia-2,4,5,8,14-pentaazatetracyclo[8.7.0.0^{2,6}.0^{11,16}]heptadeca-1(10),3,5,8,11(16)-pentaene
bn50739
bn-50739
4h-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(2-((3,4-dimethoxyphenyl)thio)-1-thioxoethyl)-7,8,9,10-tetrahydro-1-methyl-
bn 50739
tetrahydro-4,7,8,10 methyl-(chloro-2-phenyl)-6-((3,4-dimethoxyphenyl)thio)methylthiocarbonyl-9-pyrido(4',3'-4,5)thieno(3,2-f)triazolo-1,2,4(4,3-a)diazepine-1,4
L000670
128672-07-1
DTXSID60155969
Q27075409
1-[9-(2-chlorophenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaen-14-yl]-2-(3,4-dimethoxyphenyl)sulfanylethanethione
AKOS040748031

Research Excerpts

Treatment

Pretreatment with BN 50739 (10 mg/kg, i.v.) 10 min post-trauma prolonged survival time to 3.14 +/- 0.44 h (p less than 0.01) and attenuated the accumulations of cathepsin D (5.8 vs. 5.8). pretreatment of BN50739 inhibited PAF (500 pmol/kg i.p.)-induced thrombocytopenia, leukopenia and plasma thromboxane B2 elevation in a dose-dependent manner.

ExcerptReferenceRelevance
"Pretreatment with BN 50739. (50 nmol i.c.v.) did not alter ACTH response to a 1 min ether exposure or to IL1 beta injection (2 nmol i.c.v.)."( Basal and PAF-, interleukin 1-, ether stress-induced hypothalamic pituitary adrenal secretion of conscious rat: modulation by PAF antagonists.
Dray, F; Minary, P; Rougeot, C; Tiberghein, C,
)
0.45
"Treatment with BN 50739 (10 mg/kg, i.v.) 10 min post-trauma prolonged survival time to 3.14 +/- 0.44 h (p less than 0.01) and attenuated the accumulations of cathepsin D (5.8 vs."( Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock.
Karasawa, A; Lefer, AM; Rochester, JA, 1990
)
0.93
"pretreatment of BN 50739 (3 and 10 mg/kg)."( Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo.
Farhat, M; Feuerstein, G; Rabinovici, R; Yue, TL, 1990
)
0.92
"Pretreatment with BN 50739 (3 and 10 mg/kg i.p.) inhibited PAF (500 pmol/kg i.v.)-induced thrombocytopenia, leukopenia and plasma thromboxane B2 elevation in a dose-dependent manner."( Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits.
Farhat, M; Feuerstein, G; Perera, PY; Rabinovici, R; Vogel, SN; Yue, TL, 1990
)
0.92

Compound-Compound Interactions

ExcerptReferenceRelevance
"To investigate the role and significance of PAF in the early pulmonary injury following burns combined with endotoxemia in rats."( [The role and significance of PAF in the early pulmonary injury following burns combined with endotoxemia in rats].
Chen, Y; Huang, H; Liu, Y, 1999
)
0.3
"An animal model, in which rats were subjected to 20% TBSA III degree burns combined with intraperitoneal injection of lipopolysaccharide (LPS), was used for this experiment."( [The role and significance of PAF in the early pulmonary injury following burns combined with endotoxemia in rats].
Chen, Y; Huang, H; Liu, Y, 1999
)
0.3
"PAF was one of the inflammatory mediators to precede TNF changes during burns combined with endotoxemia in the early stage of pulmonary injury."( [The role and significance of PAF in the early pulmonary injury following burns combined with endotoxemia in rats].
Chen, Y; Huang, H; Liu, Y, 1999
)
0.3
"The results suggest that PAF plays an very important pathogenic role in the early lung injury resulted from burns combined with endotoxemia."( [The role and significance of PAF in the early pulmonary injury following burns combined with endotoxemia in rats].
Chen, Y; Huang, H; Liu, Y, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" BN 50739 caused a right shift in PAF dose-response curves of platelet aggregation both in vitro and ex vivo."( Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
Farhat, M; Feuerstein, G; Rabinovici, R; Yue, TL,
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1346403Human PAF receptor (Platelet-activating factor receptor)1993Biochemical and biophysical research communications, Jan-15, Volume: 190, Issue:1
Evidence for the presence of specific high affinity cytosolic binding sites for platelet-activating factor in human neutrophils.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's42 (80.77)18.2507
2000's9 (17.31)29.6817
2010's1 (1.92)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.02 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (7.02%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (92.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]